Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11)

PLoS Medicine

Volumn 11, Issue 4, 2014, Pages

  Sibiude, Jeanne ^a,b   Mandelbrot, Laurent ^a,b,c   Blanche, Stéphane ^c,d   Le Chenadec, Jérôme ^b,e   Boullag Bonnet, Naima ^b   Faye, Albert ^c,f   Dollfus, Catherine ^g   Tubiana, Roland ^g,h   Bonnet, Damien ^c   Lelong, Nathalie ^h   Khoshnood, Babak ^h   Warszawski, Josiane ^b,e,i  

^a HÔPITAL LOUIS MOURIER   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h INSERM   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BIRTH DEFECT; CD4 LYMPHOCYTE COUNT; CONGENITAL HEART MALFORMATION; DISEASE ASSOCIATION; FEMALE; FIRST TRIMESTER PREGNANCY; GENDER; HEAD AND NECK DEFECT; HEAD AND NECK DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; NEUROLOGIC DISEASE; NEWBORN; PRENATAL EXPOSURE; PREVALENCE; PROSPECTIVE STUDY; QUESTIONNAIRE; SENSITIVITY ANALYSIS; CHEMICALLY INDUCED; CONGENITAL ABNORMALITIES; FRANCE; HEART DEFECTS, CONGENITAL; HIV INFECTIONS; PREGNANCY;

ANTI-HIV AGENTS; CONGENITAL ABNORMALITIES; FEMALE; FRANCE; HEART DEFECTS, CONGENITAL; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; PROSPECTIVE STUDIES;

EID: 84900452605     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001635     Document Type: Article

References (45)

1. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, et al. (2008) Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22: 289-299.
2. European Collaborative Study (2005) Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 40: 458-465.
3. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, et al. (2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29: 484-494.
4. Delfraissy JF (2004) Prise en charge thérapeutique des personnes infectées par le VIH. Rapport 2004. Recommandations du groupe d'experts. Paris: Flammarion Médecine-Sciences.
5. Blanche S, Tardieu M, Benhammou V, Warszawski J, Rustin P, et al. (2006) Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 20: 1685-1690.
6. Thorne C, Newell ML, (2007) Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern? Drug Saf 30: 203-213.
7. Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, et al. (2009) No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 23: 1235-1243.
8. Jao J, Abrams EJ, (2013) Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants. Pediatr Infect Dis J E-pub ahead of print. doi:10.1097/INF.0000000000000224.
9. Bristol-Myers Squibb Company (2006) Sustiva (efavirenz) capsules and tablets leaflet. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021360s014lbl.pdf. Accessed 6 July 2013.
10. Ford N, Calmy A, Mofenson L, (2011) Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 25: 2301-2304.
11. Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, et al. (2010) Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 29: 721-727.
12. Knapp KM, Brogly SB, Muenz DG, Spiegel HM, Conway DH, et al. (2012) Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 31: 164-170.
13. Antiretroviral Pregnancy Registry Steering Committee (2013) The Antiretroviral Pregnancy Registry: Interim report-1 January 1989 through 31 July 2013. Available: http://www.apregistry.com/forms/interim_report.pdf. Accessed 27 January 2014.
14. Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, et al. (2011) Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med 39: 163-170.
15. Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, et al. (2013) Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 120: 1466-1475.
16. Fernandez Ibieta M, Ramos Amador JT, Bellon Cano JM, Gonzalez-Tome MI, Guillen Martin S, et al. (2009) Birth defects in a cohort of uninfected children born to HIV-infected women. An Pediatr (Barc) 70: 253-264.
17. Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA, (2009) Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 23: 519-524.
18. Patel D, Thorne C, Fiore S, Newell ML, (2005) Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 40: 116-118.
19. Newschaffer CJ, Cocroft J, Anderson CE, Hauck WW, Turner BJ, (2000) Prenatal zidovudine use and congenital anomalies in a medicaid population. J Acquir Immune Defic Syndr 24: 249-256.
20. Yeni P, editor(2006) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts.: Flammarion, Médecine-Sciences.
21. Mayaux MJ, Teglas JP, Blanche S, (2003) Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr 34: 338-343.
22. EUROCAT (2005) EUROCAT Guide 1.3 and reference documents. Instructions for the Registration and Surveillance of Congenital Anomalies. Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf last accessed 01/27/2014.
23. EUROCAT (2012) Coding of EUROCAT Subgroups of Congenital Anomalies (Version 2012). Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf last accessed 01/27/2014.
24. MACDP (2007) Birth Defects and Genetic Diseases Branch 6-digit code for Reportable Congenital Anomalies.Available at: http://www.cdc.gov/ncbddd/birthdefects/documents/MACDPcode0807.pdf last accessed 01/27/2014.
25. Scheuerle A, Tilson H, (2002) Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf 11: 465-475.
26. StataCorporation (2009) Stata 11.0 for Windows. College Station, Texas: Stata Corporation.
27. Joao EC, Calvet GA, Krauss MR, Freimanis Hance L, Ortiz J, et al. (2010) Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 53: 176-185.
28. Du ZD, Roguin N, Barak M, Bihari SG, Ben-Elisha M, (1996) High prevalence of muscular ventricular septal defect in preterm neonates. Am J Cardiol 78: 1183-1185.
29. Laas E, Lelong N, Thieulin AC, Houyel L, Bonnet D, et al. (2012) Preterm Birth and Congenital Heart Defects: A Population-based Study. Pediatrics Oct;130 (4):: e829-37.
30. Yeni P (2010) Prise en charge médicale des personnes infectées par le VIH: Rapport 2010-Recommandations du groupe d'experts. Paris: La Documentation Française.
31. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J, (2001) The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol 15: 637-646.
32. Forna F, McConnell M, Kitabire FN, Homsy J, Brooks JT, et al. (2006) Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: Implications for resource-limited settings. AIDS Rev 8: 24-36.
33. Jungmann EM, Mercey D, DeRuiter A, Edwards S, Donoghue S, et al. (2001) Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 77: 441-443.
34. Richardson MP, Osrin D, Donaghy S, Brown NA, Hay P, et al. (2000) Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol 93: 215-217.
35. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, et al. (2011) Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 57: 76-85.
36. Desai VG, Lee T, Moland CL, Branham WS, Mittelstaedt RA, et al. (2012) Evaluation of hepatic mitochondria and hematological parameters in zidovudine-treated B6C3F(1) mice. AIDS Res Treat 2012: 317695.
37. Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, et al. (2011) Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 56: 183-187.
38. Houyel L, Khoshnood B, Anderson RH, Lelong N, Thieulin AC, et al. (2012) Population-based evaluation of a suggested anatomic and clinical classification of congenital heart defects based on the International Paediatric and Congenital Cardiac Code. Orphanet J Rare Dis 6: 64.
39. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed 27 January 2014.
40. Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E, (2002) Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16: 299-300.
41. Saitoh A, Hull AD, Franklin P, Spector SA, (2005) Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 25: 555-556.
42. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission (2012) Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available: http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0. Accessed 27 January 2014.
43. Riecke K, Schulz TG, Shakibaei M, Krause B, Chahoud I, et al. (2000) Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology 62: 291-300.
44. EUROCAT (2012) Prevalence tables. Available: http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Accessed 27 January 2014.
45. Rothman KJ, (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43-46.